|
Market Data
Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and marketing medicines to address significant unmet medical needs globally. The company's core business centers on treatments for viral diseases, including HIV/AIDS and hepatitis, with a portfolio of established therapies such as Biktarvy, Genvoya, and Epclusa. Beyond virology, Gilead offers oncology products like Yescarta and Trodelvy, as well as treatments for pulmonary arterial hypertension and invasive fungal infections. Gilead leverages strategic collaborations with other pharmaceutical and biotechnology companies, including Arcus Biosciences and Merck, to expand its research and development capabilities and pipeline of potential future therapies. Founded in 1987, the company is headquartered in Foster City, California.
GILD is currently trading at $137.88, giving Gilead Sciences, Inc. a market cap of 170.84B and a P/E ratio of 20.1. Today's range spans $136.69–$139.76, with shares opening at $138.95 and moving up $0.24 (0.2%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 76/100.
Over the past year GILD has traded between $93.37 and $157.29 - the current price is +47.7% off the 52-week low and -12.3% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $158.36 (range $123.00–$180.00), implying upside of +14.9%.
Risk is elevated for Gilead Sciences, Inc. (GILD) right now - bearish technical setup (32/100, SELL), bullish sentiment (76/100), price $137.88 (in the upper portion of its 52-week range). The current P/E ratio stands at 20.1. At 170.84B in Healthcare market cap, the 52-week range of $93.37–$157.29 defines where structural demand might resurface - because at this capitalization tier, buyers don't disappear, they just move their bids to different price levels.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.91 | - | - |
| Q4'25 | $1.98 | $1.86 | -6.2% |
| Q3'25 | $2.14 | $2.47 | +15.7% |
| Q2'25 | $1.96 | $2.01 | +2.7% |
| Q1'25 | $1.78 | $1.81 | +1.9% |
| Q4'24 | $1.70 | $1.90 | +11.7% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $6.9B | - | - |
| Q4'25 | $6.9B | $7.9B | +14.1% |
| Q3'25 | - | $7.8B | - |
| Q2'25 | - | $7.1B | - |
| Q1'25 | - | $6.7B | - |
| Q4'24 | - | $7.6B | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).